Saturday, September 7, 2024
9/7/2024
ABSTRACT The rapid rise of extended spectrum beta-lactamase-producing (ESBL) Enterobacteriaceae is severely threatening the way we treat common infectious diseases. Enterobacteriaceae such as Escherichia coli (E. coli) are a major cause of infections such as bacteremia, meningitis, and urinary tract infections in neonates. Gut colonization with ESBL E. coli is a risk factor for these invasive infections. Additionally, infants who are asymptomatically colonized with ESBL E. coli also contribute to the community reservoir of these strains. Several recent studies have shown that acquisition and persistence of gut colonization with ESBL E. coli can occur even in the absence of antibiotic exposure, traditionally considered a key risk factor. At birth the neonatal gut is only sparsely populated with microbes, and therefore provides a unique environment for acquisition of ESBL E. coli due to the limited competition from other microbes. A significant proportion of infants who acquire ESBL E. coli early in life remain persistently colonized with them. However, the impact of early life acquisition on the rapidly developing infant gut microbiome is not well studied, especially in the setting of varying age of acquisition and nutritional intake. Previous work in the Arshad laboratory using a murine model of early life E. coli acquisition has shown that several ESBL E. coli persistently colonize the mouse gut through adulthood with a significantly higher burden of colonization compared to commensal non-ESBL E. coli. In vitro studies show that some of the strains adept in gut colonization are also able to out compete non-ESBL E. coli in a limited nutrient growth media as well as in vivo in the animal model. Perinatal transmission of at least one ESBL E. coli in our murine model results in an overabundance of E. coli in the infant gut microbiome and a displacement of usual commensal microbes. This proposal aims to utilize clinically relevant ESBL E. coli, genomic sequencing, and animal models to 1) determine the gut microbiome characteristics associated with ESBL E. coli colonization during the early life period, and 2) assess gut colonization with ESBL E. coli and impact on microbiome according to age and nutritional status. These objectives will be achieved by building on existing collaborations between the Arshad lab (expertise in bacterial pathogenesis and animal models) and DePlaen lab (expertise in mouse gut nutrition) at Lurie Children’s Hospital, and Hartmann lab at Northwestern University (expertise in bacterial genomics, next-generation sequencing), and Grobe lab at University of Wisconsin (expertise in caloric assessment of stool). We anticipate that the results from the proposed experiments will provide in vivo evidence of the long-term impact of gut colonization with ESBL E. coli on the infant gut microbiome. Further, the results of the proposed study will aid in developing nutritional interventions and/or identification of commensal microbes that may be used as probiotics, to prevent long-term colonization with ESBL E. coli.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
